Last reviewed · How we verify
NCT06978803: DISCOURSE-NB
HYEEG Discourse in Psychosis: A Neurobehavioural Study
trial in Psychosis in 110 participants. Currently enrolling.
22 October 2025
Quick facts
| Lead sponsor | Douglas Mental Health University Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 16 January 2024 |
| Primary completion | 22 October 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Canada |
Conditions studied
- Psychosis — all drugs for Psychosis →
- Schizophrenia Disorders — all drugs for Schizophrenia Disorders →
Sponsor
Douglas Mental Health University Institute
Who can join
Adults 18 to 60, any sex, with Psychosis or Schizophrenia Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multimodal study explores the mechanisms underlying social dysfunction in individuals with schizophrenia. It focuses on the relationship between disorganized communication and social interaction, aiming to identify measurable markers of disorganized communication and link them to clinical symptoms and social functioning. Key Research Questions: How do neural and behavioural synchrony contribute to social impairments in schizophrenia? What roles do interbrain synchrony, motor imitation, reaction time, and verbal coherence play in disorganized communication? Participants will: 1. Engage in structured and semi-structured real-time social interactions while undergoing dual-brain electroencephalogram (EEG) hyperscanning to measure neural and behavioural activity. 2. Perform nonverbal tasks such as motor imitation and reaction time assessments to investigate coordination and behavioural synchrony patterns. 3. Participate in a clinical interview that evaluates verbal production, thought coherence, and speech organization. By combining these assessments, the study aims to advance our understanding of how social and communication impairments manifest in schizophrenia. The findings will contribute to developing improved diagnostic tools and targeted interventions, ultimately supporting patients in achieving better social functioning and quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06978803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psychosis
Currently open trials in the same condition.
- NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
- NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
- NCT07196462 — Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia · NA · recruiting
- NCT07364825 — Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care · NA · recruiting
Other Douglas Mental Health University Institute trials
Trials by the same sponsor.
- NCT07002996 — Spatial Memory Training and Cognitive Function · NA · recruiting
- NCT06978465 — DIALOG: Understanding Disorganisation: A Language-focused Global Initiative in Psychosis · not yet recruiting
- NCT06978452 — Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories · recruiting
- NCT06978894 — Predicting Psychotic Relapse Using Speech-Based Early Detection · recruiting
- NCT06893393 — Virtual Travel Into Nature for Individuals With Lived Experience of Severe Mental Disorders · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06978803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Douglas Mental Health University Institute
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06978803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing